Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals Ireland Limited

Axsome Malta Ltd.

Jazz Pharmacuticals, Inc.

Jazz Pharmaceuticals International Iii Limited

Jazz Pharma Ireland Limited

Jazz Pharmaceuticlas Ireland Limited

Clark Patrick Allphin

James Frederick Pfeiffer

Michael DesJardin

Edwin Gerard Walsh

Scott Bura

Maura Patricia Murphy

Andrea Marie Rourke

Gene Curtis Jamieson

Sigridur Olafsdottir

Michael Des Jardin

Katayoun Zomorodi

Gunjan H Junnarkar

Mark Eller

Cuiping Chen

Roman Skowronski

Alya Khan McGinlay

Alya Kahn McGinlay

Maura Murphy

Andrea Rourke

The invention relates to modified release oral formulations of therapeutic agents, including gamma hydroxybutyrate (GHB), paracetamol, codeine or oxycodone, which are resistant to alcohol induced dose dumping. Provided are formulations that have improved resistance to rapid release of the active ingredient in the presence of increasing amounts of alcohol. Also provided are formulations that can reduce or prevent the release of the active ingredient following exposure to alcohol-containing media. The invention also relates to methods of making the formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Alcohol-resistant drug formulations

The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Formulations of (R)-2-amino-3-phenylpropyl carbamate

A device includes a reservoir configured to store a drug formulation including at least one abuse-preventing additive. The device further includes means configured to remove the at least one abuse-preventing additive. The device further includes means configured to prevent access to the drug formulation.

Devices and methods for facilitating and controlling use of a medication

Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

The present application relates to GHB formulations and methods for manufacturing the same.

GHB formulation and method for its manufacture

Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.

Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances

Growing community of inventors

Seattle, WA, United States of America

Clark Patrick Allphin